Benlysta, BMS melanoma drug win accelerated FDA review

Two of the most closely watched therapies now awaiting a final decision at the FDA won an accelerated regulatory review. Human Genome Sciences will have four months shaved off the usual review schedule for Benlysta, which could be the first new lupus drug to gain approval in half a century. The FDA has marked December 9th as its deadline on Benlysta. And Bristol-Myers Squibb has received a significant leg up in its quest to gain quick U.S. approval of ipilimumab for melanoma. The FDA has...